Metabolomics in pharmaceutical research and development

被引:41
作者
Puchades-Carrasco, Leonor [1 ]
Pineda-Lucena, Antonio [1 ]
机构
[1] Ctr Invest Principe Felipe, Struct Biochem Lab, Valencia, Spain
关键词
DRUG DISCOVERY; BIOMARKER DISCOVERY; MASS-SPECTROMETRY; SYSTEMS BIOLOGY; MATERNAL URINE; D-CYCLOSERINE; NMR; METABONOMICS; PLASMA; TOOL;
D O I
10.1016/j.copbio.2015.04.004
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Metabolomics has significant potential in pharmaceutical and clinical research, including the identification of new targets, the elucidation of the mechanism of action of new drugs, the characterization of safety and efficacy profiles, as well as the discovery of biomarkers for early disease diagnosis, prognosis, patient stratification, and treatment response monitorization. Metabolomics involves the analysis of small molecules and can lead to an improved understanding of drug candidate actions and to a better selection of targets. Although the application of metabolomics in the pharmaceutical industry is still at its infancy, this experimental approach has the possibility to transform our knowledge of drug action through the examination of drug-induced metabolic pathways associated to both drug efficacy and adverse drug reactions.
引用
收藏
页码:73 / 77
页数:5
相关论文
共 63 条
  • [21] Metabolomics in Plants and Humans: Applications in the Prevention and Diagnosis of Diseases
    Gomez-Casati, Diego F.
    Zanor, Maria I.
    Busi, Maria V.
    [J]. BIOMED RESEARCH INTERNATIONAL, 2013, 2013
  • [22] UPLC-MS metabolic profiling of second trimester amniotic fluid and maternal urine and comparison with NMR spectral profiling for the identification of pregnancy disorder biomarkers
    Graca, Goncalo
    Goodfellow, Brian J.
    Barros, Antonio S.
    Diaz, Silvia
    Duarte, Iola F.
    Spagou, Konstantina
    Veselkov, Kirill
    Want, Elizabeth J.
    Lindon, John C.
    Carreira, Isabel M.
    Galhano, Eulalia
    Pita, Cristina
    Gil, Ana M.
    [J]. MOLECULAR BIOSYSTEMS, 2012, 8 (04) : 1243 - 1254
  • [23] Nanostructure-Initiator Mass Spectrometry Metabolite Analysis and Imaging
    Greving, Matthew P.
    Patti, Gary J.
    Siuzdak, Gary
    [J]. ANALYTICAL CHEMISTRY, 2011, 83 (01) : 2 - 7
  • [24] Metabolomics in cell culture-A strategy to study crucial metabolic pathways in cancer development and the response to treatment
    Halama, Anna
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2014, 564 : 100 - 109
  • [25] Use of NMR metabolomics to analyze the targets of D-cycloserine in mycobacteria: Role of D-alanine racemase
    Halouska, Steven
    Chacon, Ofelia
    Fenton, Robert J.
    Zinniel, Denise K.
    Barletta, Raul G.
    Powers, Robert
    [J]. JOURNAL OF PROTEOME RESEARCH, 2007, 6 (12) : 4608 - 4614
  • [26] Predicting the in Vivo Mechanism of Action for Drug Leads Using NMR Metabolomics
    Halouska, Steven
    Fenton, Robert J.
    Barletta, Raul G.
    Powers, Robert
    [J]. ACS CHEMICAL BIOLOGY, 2012, 7 (01) : 166 - 171
  • [27] Network-Based Approaches in Drug Discovery and Early Development
    Harrold, J. M.
    Ramanathan, M.
    Mager, D. E.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (06) : 651 - 658
  • [28] The role of metabolomics in neurological disease
    Hassan-Smith, Ghaniah
    Wallace, Graham R.
    Douglas, Michael R.
    Sinclair, Alexandra J.
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2012, 248 (1-2) : 48 - 52
  • [29] Metabolic phenotyping in health and disease
    Holmes, Elaine
    Wilson, Ian D.
    Nicholson, Jeremy K.
    [J]. CELL, 2008, 134 (05) : 714 - 717
  • [30] Metabolomic evaluation of the response to endocrine therapy in patients with prostate cancer
    Huang, Gang
    Liu, Xinru
    Jiao, Li
    Xu, Chuanliang
    Zhang, Zhongxiao
    Wang, Linhui
    Li, Yun
    Yang, Chun
    Zhang, Weidong
    Sun, Yinghao
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2014, 729 : 132 - 137